Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered BIOLINERX LTD/S from a buy rating to a hold rating in a research report on Tuesday, July 16th. HC Wainwright set a $3.00 price target on BIOLINERX LTD/S and gave the company a buy rating in a report on Tuesday, May 14th. Finally, Maxim Group reissued a buy rating and set a $10.00 price target on shares of BIOLINERX LTD/S in a report on Monday, July 22nd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $4.13.
NASDAQ BLRX traded down $0.09 during trading hours on Thursday, hitting $3.86. The company had a trading volume of 16,872 shares, compared to its average volume of 72,367. BIOLINERX LTD/S has a fifty-two week low of $3.47 and a fifty-two week high of $27.60. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.18. The business has a fifty day moving average of $1.73. The company has a market cap of $29.54 million, a price-to-earnings ratio of -1.23 and a beta of 1.48.
Several institutional investors and hedge funds have recently modified their holdings of BLRX. Deutsche Bank AG acquired a new position in shares of BIOLINERX LTD/S during the fourth quarter valued at $26,000. NEXT Financial Group Inc increased its holdings in shares of BIOLINERX LTD/S by 82.5% during the second quarter. NEXT Financial Group Inc now owns 73,000 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 33,000 shares during the period. Finally, Delek Group Ltd. acquired a new position in shares of BIOLINERX LTD/S during the first quarter valued at $92,000.
About BIOLINERX LTD/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Featured Article: Book Value Of Equity Per Share – BVPS Explained
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.